Gene · 51564
Papers2,197
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 2,197
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cortical type: a conceptual tool for meaningful biological interpretation of high-throughput gene expression data in the human cerebral cortex. | Front Neuroanat | 2023 | 37426901 | PubTator, text mining | PubMed |
| Targeting histone deacetylases for cancer therapy: Trends and challenges. | Acta Pharm Sin B | 2023 | 37425042 | PubTator, text mining | PubMed |
| Tropolones and Thailandepsin B as Lead-like Natural Compounds in the Development of Potent and Selective Histone Deacetylase Inhibitors. | Curr Drug Targets | 2023 | 37424350 | PubTator, text mining | PubMed |
| RNA m5C methylation orchestrates BLCA progression via macrophage reprogramming. | J Cell Mol Med | 2023 | 37408139 | PubTator, text mining | PubMed |
| Metabolo-epigenetic interplay provides targeted nutritional interventions in chronic diseases and ageing. | Front Oncol | 2023 | 37404756 | PubTator, text mining | PubMed |
| Advances in epigenetic modifications of autophagic process in pulmonary hypertension. | Front Immunol | 2023 | 37398657 | PubTator, text mining | PubMed |
| Histone modifications in drug-resistant cancers: From a cancer stem cell and immune evasion perspective. | Exp Mol Med | 2023 | 37394580 | PubTator, text mining | PubMed |
| Molecular Mechanisms and Risk Factors Related to the Pathogenesis of Peyronie's Disease. | Int J Mol Sci | 2023 | 37373277 | PubTator, text mining | PubMed |
| Role of Histone Deacetylases in the Pathogenesis of Salivary Gland Tumors and Therapeutic Targeting Options. | Int J Mol Sci | 2023 | 37373187 | PubTator, text mining | PubMed |
| Histone Deacetylases (HDAC) Inhibitor-Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor. | Genes (Basel) | 2023 | 37372475 | PubTator, text mining | PubMed |
| The Interplay between Dysregulated Metabolism and Epigenetics in Cancer. | Biomolecules | 2023 | 37371524 | PubTator, text mining | PubMed |
| K235 acetylation couples with PSPC1 to regulate the m6A demethylation activity of ALKBH5 and tumorigenesis. | Nat Commun | 2023 | 37369679 | Swiss-Prot, curated | PubMed |
| Multi-Omic Analysis of CIC's Functional Networks Reveals Novel Interaction Partners and a Potential Role in Mitotic Fidelity. | Cancers (Basel) | 2023 | 37345142 | PubTator, text mining | PubMed |
| Repurposing of neprilysin inhibitor 'sacubitrilat' as an anti-cancer drug by modulating epigenetic and apoptotic regulators. | Sci Rep | 2023 | 37336927 | PubTator, text mining | PubMed |
| Salt-inducible kinase inhibition promotes the adipocyte thermogenic program and adipose tissue browning. | Mol Metab | 2023 | 37321371 | PubTator, text mining | PubMed |
| Faecal Microbiota transplantation affects liver DNA methylation in Non-alcoholic fatty liver disease: a multi-omics approach. | Gut Microbes | 2023 | 37317027 | PubTator, text mining | PubMed |
| Combat Against Gynecological Cancers with Blood Vessels as Entry Point: Anti-Angiogenic Drugs, Clinical Trials and Pre-Clinical Nano-Delivery Platforms. | Int J Nanomedicine | 2023 | 37312935 | PubTator, text mining | PubMed |
| Endothelin-1 induces connective tissue growth factor expression in human lung fibroblasts by disrupting HDAC2/Sin3A/MeCP2 corepressor complex. | J Biomed Sci | 2023 | 37312162 | PubTator, text mining | PubMed |
| An Overview of the Potential Medicinal and Pharmaceutical Properties of Ru(II)/(III) Complexes. | Int J Mol Sci | 2023 | 37298471 | PubTator, text mining | PubMed |
| Non-oncology drug (meticrane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells. | Front Oncol | 2023 | 37274234 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51564/papers?page=11